Tag Archives: COVID-19

Chinese are angry at South Korea and Japan

Travel restrictions launched in the wake of China’s border reopening may be affecting where people there are booking trips.

But it’s not out of spite, said several Chinese travelers who spoke to CNBC.

It’s because some countries aren’t letting them in easily, they said.

‘I think it’s unfair’

Reactions from Chinese travelers who spoke to CNBC were varied, ranging from indifference to confusion to anger.

“Of course, I think it’s unfair,” said one citizen, who asked to be called Bonnie. “But at the same time, we understand what’s going on.”

So far, more than a dozen countries have announced new rules for travelers departing from China. Last week, the European Union recommended that its members require Chinese travelers to take Covid tests before entering.

But Covid tests aren’t the problem, Shaun Rein, managing director of China Market Research Group, told “Squawk Box Asia” on Monday. It’s that “these policies are directed only towards mainland Chinese,” he said.

South African Mansoor Mohamed, who lives in China, agreed. “It is relatively easy and cheap to do a Covid test in China, so it will not affect my travel planning,” he said.

However, I know that many patriotic Chinese colleagues and friends will avoid those countries for now because the practice of only testing passengers arriving from China is discriminatory,” he said.

Of course, China requires travelers to test negative before entering China, and has for three years.

The difference, Mohamed said, is that “every arrival [to China], including Chinese nationals … [is] subjected to the same rules.”

Where the Chinese are going

Gao Dan told CNBC she is planning to travel out of the province of Qinghai for the first time in more than two years. But she said she’s staying in China, adding that she “hasn’t looked into what other countries’ travel policies are,” according to a CNBC translation.

Others are booking trips abroad, but some not to their first-choice destinations — namely Japan and South Korea.

One traveler, named Bonnie, told CNBC her friends in China are going to Thailand rather than South Korea, even though “they wouldn’t have considered Thailand” before.

Tuul & Bruno Morandi | The Image Bank | Getty Images

“When China said they were opening the borders in January, all my friends said they’re going to Japan and Korea,” said Bonnie.

But they couldn’t get visas, she said. “So they are now going to Thailand.”   

Rein said Chinese travelers are now headed to Singapore and Thailand because “both countries are welcoming us.”

Of the top destinations Chinese nationals searched after the border reopening announcement, those are the only two that haven’t imposed new restrictions on incoming Chinese travelers.

Data shows search interest for outbound flights from mainland China rose by 83% in the 11 days after the announcement, compared with the 14 days before it, according to data from Trip.com Group.

During this period, search interest for Thailand and Singapore grew by 176% and 93%, respectively, according to the company.

Angrier at some more than others

Chinese officials called the rules from South Korea and others “excessive” and “discriminatory.”

But South Korea refutes claims of discrimination. Seung-ho Choi, a deputy director at the Korea Disease Control and Prevention Agency, pointed out to CNBC that the country’s rules apply to “Korean nationals and non-Korean nationals coming from China. … There is no discrimination for nationality in this measure.”

“China’s Covid situation is still worsening,” he said. The number of people traveling from China to Korea who tested positive for Covid-19 went up 14 times from November to December, he said.

The Prime Minister’s Office of Japan did not respond to CNBC’s request for comment. A representative at Japan’s Embassy in Singapore told CNBC that Japan is processing Chinese travel visa requests as usual.

Citing a discrepancy in infection information from China, Japan Prime Minister Fumio Kishida told reporters on Dec. 27: “In order to avoid a sharp increase in the influx of new cases into the country, we are focusing efforts on entry inspections and airports,” according to an article published by Nikkei Asia.

Both Japan and South Korea have taken conservative stances toward the Covid pandemic.

Japan, in particular, has been sluggish to bounce back to pre-pandemic life, with residents showing little enthusiasm when its own border fully reopened in October 2022.  

‘A political issue’

Rein told “Squawk Box Asia” that the rules are not just about tourism.

“This is a political issue,” he said, adding that he expects Japanese stocks to be affected, singling out two cosmetics names.

Read more about China’s reopening

“I would be cautious on Shiseido. I’d be cautious on Kose, because there are going to be some boycotts,” he said. Shares of Kose were lower on the Tokyo stock exchange on Tuesday, but Shiseido was higher.

Rein said animosity toward South Korea and Japan will be short-lived.

“It’ll take about three months for the anger to dissipate,” he said. “There’s going to be massive revenge travel outside to Korea to Japan — if those two countries treat Chinese properly.”

New Zealander Darren Straker, who lives and works in Shanghai, said he, too, believes the policies are politically motivated, calling them a “last sad gasp [as] the Covid geopolitical door closes.”



Read original article here

New COVID Variant Sends NYC Case Rates Soaring; Hospitalizations High – NBC New York

What to Know

  • You’ve probably heard about the XBB.1.5 variant; it’s the latest “most transmissible COVID variant yet” and appears to be better at binding to human cells, which may make it more adept at infecting
  • There’s no evidence at this point that the strain, a combination of two prior omicron subvariants, is more lethal or more likely to cause COVID complications, but as a top White House official said last week, if you haven’t been vaccinated or infected lately, your protection probably isn’t so good
  • Nowhere is XBB.1.5 more prevalent than in the northeastern United States, according to the CDC — and rolling hospitalization and death rates, along with cases, are climbing accordingly

COVID-19 hospitalizations in New York and New Jersey have soared to 11-month highs as the most transmissible variant yet, a combination of two prior omicron strains, fuels yet another infection wave nearly three full years into the pandemic, the latest federal health data show.

Deaths are also climbing, with weekly fatality reports for both states currently at their highest levels since early last year, according to the CDC. In New York City, the rolling COVID fatality average is the highest it’s been since February 2022, while rolling hospitalizations are at a height not seen since the downswing of the initial omicron wave.

CDC COVID guidelines say face masks should be worn across the board in New York City, Long Island and much of the Hudson Valley, given the high spread rate. And the entire state of New Jersey is at the agency’s highest risk level, its latest data shows. While elected officials and their health departments have advised people to follow those guidelines, especially if they’re more vulnerable in terms of age or underlying conditions, no new mandates have been issued.


CDC

COVID community levels in NY



CDC

COVID community levels in NJ


And no new mandates are expected, either, at this point in the pandemic.

New York Gov. Kathy Hochul and New Jersey Gov. Phil Murphy, both of them Democrats, are each set to deliver their State of the State addresses on Tuesday. It remains to be seen whether the ongoing COVID response will once again play a feature role in those speeches. Given these charts, the odds are fairly likely.

NEW YORK STATE COVID TRENDS (via CDC)

HOSPITALIZATIONS



CDC


CASES AND DEATHS


CDC

COVID cases and deaths in New York via CDC


Last week, New York state’s Department of Health announced the XBB.1.5 variant is far and away the most dominant strain locally, accounting for more than 50% of statewide infections. That share is likely considerably higher, given the relatively low proportion of positive tests that undergo the exhaustive genetic sequencing process to isolate variants.

The same can be said for New Jersey, where the 38.4% share of sequences cases tied to XBB.1.5 reflects data not updated since mid-December. In New York City, where data also lags, XBB.1.5’s prevalence is likely well above the 68% share that the health department last updated on Christmas Eve.

NEW JERSEY COVID TRENDS


CDC

New Jersey COVID hospitalization trends



CDC

New Jersey COVID case and death trends


The latest CDC data suggests that XBB.1.5 is spreading in the northeastern United States at a much higher rate than the rest of the country, accounting for up to 81% of cases in the region comprising New York and New Jersey compared with a 43% high estimate for the nation.

While there is “not yet clear evidence,” according to New York state, that XBB.1.5 significantly affects COVID’s virulence or disease severity, early data does indicate it is more infectious than other circulating variants. The fact it has emerged at a time when both COVID and flu cases remain high is further cause for heightened caution, it says.

New York City positivity rates are bearing out the transmissibility concerns, with more than a third of neighborhoods across the five boroughs seeing those numbers in excess of 20% — and some spots topping 30% positivity.

NYC COVID VARIANT AND HOSPITALIZATION DATA


NYC

This chart represents COVID variants in NYC. The top line is XBB.1.5.



NYC Health Department

NYC COVID hospitalization trends


Omicron is still classified as a variant of concern according to the CDC and the World Health Organization. That strain, which first emerged in South Africa in November 2021, though likely was there earlier, is the only variant of concern currently in circulation, according to WHO.

To be a variant of concern, WHO says a strain must be associated with one or more of the following changes at a degree of global significance:

  • Increase in transmissibility or detrimental change in COVID-19 epidemiology; OR
  • Increase in virulence or change in clinical disease presentation; OR
  • Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics

The CDC said the new COVID-19 variant is responsible for 75% of new cases.

Given their level of infectiousness and ongoing mutation, WHO advises each omicron descendant be monitored distinctly. That’s what officials in New York and New Jersey continue to do as they plead with the public to double down on the mitigation factors that have proven to work since the onset of the pandemic, from hand-washing and staying home when sick to vaccination, masking up in crowded areas and getting tested regularly.

Hochul continues to urge New Yorkers — and so does the White House — to get their updated bivalent booster shots if they haven’t already (see vaccine data). The head of the White House Task Force on COVID recently underscored the point, saying if you haven’t been infected lately or had that booster, you’re likely not protected from XBB.1.5.

Overall, experts say that healthy, vaccinated people still are at much lower risk for COVID complications than immunocompromised or un- and undervaccinated people.

As Hochul said in her latest COVID update, “I urge everyone to remain vigilant and continue to use all available tools to keep themselves, their loved ones and their communities safe and healthy. Stay up to date on vaccine doses, and test before gatherings or travel. If you test positive, talk to your doctor about potential treatment options.”


Read original article here

Measles Outbreak In Ohio Has Health Officials Worried

A measles outbreak among dozens of unvaccinated children in Ohio has local health officials concerned about a deepening distrust of vaccines among some parents. With vaccination rates slipping around the country, more Americans are beginning to question the value of vaccine requirements for kids ― putting at risk a growing group of young children with no immunity to the virus.

Decades-old wariness of the measles vaccine ― based on well-funded false claims about a nonexistent link to autism ― has combined with the backlash against COVID vaccination rules and other pandemic-related hurdles to result in a slowdown in childhood vaccination rates.

Taken together, these factors increase the risk of outbreaks like the one in Ohio. There have been 82 diagnosed measles cases in the state, almost all in the Columbus area, and the vast majority in patients 5 years old or younger. Most of the cases have occurred in the past two months, leading to the hospitalization of 33 children, primarily for dehydration, diarrhea and pneumonia.

Seventy-five of the 82 kids were completely unvaccinated and four were partially vaccinated, having received one of two measles, mumps and rubella, or MMR, shots. Measles is remarkably contagious, infecting up to 90% of unimmunized people who come close to an infected person.

Nearly two dozen of the Ohio patients were too young to be protected. According to state data, there have been 23 measles cases among children younger than 1 year. Children typically receive their first measles shot when they’re between 12 and 16 months old. When measles came to town, those infants ― and other children too immunocompromised to handle certain vaccines ― had to rely on protection from their neighbors and classmates.

“When a parent makes a decision not to have their child vaccinated, they’re not realizing the implications of that decision. If their child can get that infection, it doesn’t just have an impact on their child or their household, but it can impact their school, it can impact their community,” Mysheika Roberts, who leads Columbus’s public health department, told HuffPost.

The Ohio outbreak is a case in point: Between June and October, the first four measles cases since 2019 emerged in the state, all of them among unvaccinated, unrelated people who’d traveled to a measles-endemic country and returned to the U.S. By early November, four cases in children with no travel history were linked to a local day care. By the end of that month, there were 46 confirmed cases, and the exposure sites had multiplied, too, including a mall, a church and a supermarket.

At this point, the total number of cases has stayed the same for several days. But holiday travel and measles’ long incubation period ― up to 21 days ― means the virus may well still be spreading undetected.

“We’ve got a ways to go,” Roberts said. “Anything could happen.”

The COVID Vaccine Dip

Measles was technically declared eliminated in the U.S. in 2000.

But outbreaks have popped up over the last two decades. The worst one hit hundreds of people in New York and New Jersey in 2019, just a few months before COVID-19 spread through the area. The measles outbreak occurred largely among the Orthodox Jewish community; other outbreaks have similarly occurred within close-knit communities, such as the Amish.

And nationwide, vaccine trends have taken a troubling turn since the COVID-19 pandemic began.

During the 2020-21 school year, the estimated rate of kindergarteners who met state-level vaccine requirements ― MMR, chicken pox and DTaP, the vaccine for diphtheria, tetanus and whooping cough ― fell by roughly a percentage point across the board, according to the Centers for Disease Control and Prevention. The percentage of kindergartners with two doses of the measles vaccine fell from 95.2% the year before to 93.9%.

But the top-line numbers belie the pockets of low coverage across the country. On top of the 2.2% of kindergartners nationwide who had at least one vaccination exemption ― 86% of which were classified as non-medical ― an additional 3.9% without an exemption weren’t up to date on their measles shots, according to the CDC data.

“This means there are 35,000 more children in the United States during this time period without documentation of complete vaccination against common diseases,” Georgina Peacock, the immunization services director at the CDC, said at a news briefing in April.

And that’s not counting an approximately 10% drop in kindergarten enrollment that year ― representing roughly 400,000 kids, including an unknown number who were behind on their vaccines.

Several things could factor into the nationwide dip in MMR vaccination rates. But it appears the backlash to COVID-19 public health measures ― particularly vaccine mandates ― played a significant role. As COVID vaccines arrived on the scene, so did fear-mongering: Social media and online forums were full of erroneous claims about the vaccines not being properly vetted and containing microchips that could track individuals. One Ohio doctor is currently under investigation by the state’s medical board after speculating that the vaccine had magnetized its recipients.

Dr. Sherri Tenpenny, a Cleveland-based osteopathic doctor, is now under state medical board investigation after making false claims about COVID-19 vaccines.

The Ohio Channel via via Associated Press

Polling by the Kaiser Family Foundation last month found that 26% of adults who have not gotten vaccinated against COVID-19 think the risks of the MMR vaccine outweigh the benefits. And while adults overall still overwhelmingly think the MMR vaccine’s benefits outweigh its risks (85% to 12%), a striking number have changed their minds about vaccine requirements in the past three years. Twenty-eight percent of adults agree with the sentiment “Parents should be able to decide not to vaccinate their children, even if that may create health risks for other children and adults,” up 12% from the findings of a 2019 Pew Research Center poll, Kaiser Family Foundation noted.

Stephanie Stock, president of the anti-vaccine-mandate group Ohio Advocates for Medical Freedom, told HuffPost in an email that various COVID-related claims by health authorities, such as changing guidance on masks, “certainly led people to question the level of trust to place in them.”

“Many Ohioans came to OAMF during the pandemic to find out what medical choice rights they have and how to become politically involved in fighting to protect those rights,” Stock said. Asked whether the anti-vaccine movement is responsible for an increased risk to kids who can’t get vaccinated because they are too young or immunocompromised, Stock wrote that her group “believes parents, not communities, are responsible for a child’s health, and that those parents are best suited to make the health decisions they feel are in the best interest of that child.”

It’s too early to say how much of an overlap there is between Americans who have hesitated to get vaccinated for COVID and those who have delayed or skipped their kids’ MMR shots. But according to Michael Osterholm, director of the Center for Infectious Disease Research and Policy, “there is this sense right now that much of the negative energy that has grown up around COVID vaccines is now spilling over substantially to childhood immunizations.”

“We’re seeing in more and more counties around the country lower levels of immunization for routine childhood vaccines that really parallels the same lack of support for COVID vaccines,” Osterholm told HuffPost.

“There is this sense right now that much of the negative energy that has grown up around COVID vaccines is now spilling over substantially to childhood immunizations.”

– Michael Osterholm, director of the Center for Infectious Disease Research and Policy

Ohio doesn’t require vaccination reporting statewide, so it’s difficult to know the state’s actual vaccination rates for measles or other viruses.

But Ohio schools do keep data on students’ required vaccinations. Data provided to HuffPost by the Ohio Department of Health show a noticeable drop in vaccination among kindergartners since the COVID pandemic began. From the 2019-2020 school year to the 2021-22 school year, the rate of kindergarten students up to date on their MMR, polio and DTaP vaccines fell from over 92% to under 89% for all three vaccines. Kindergarteners with up-to-date chickenpox vaccines fell from 91.9% to 87.8%. And hepatitis B vaccination rates fell from 94.9% to 92.7% over the same period.

“This [outbreak] is something that’s a direct consequence of being behind in vaccinations,” said Alexandria Jones, assistant health commissioner and director of prevention & wellness at Franklin County Public Health.

Much of measles vaccine hesitancy in the U.S. comes down to a single word: autism.

There is no evidence ― none ― of a link between the measles vaccine and autism spectrum disorder. But the myth has been around since Andrew Wakefield, a since-discredited British physician, claimed in a 1998 study that such a connection existed. That study was later retracted by The Lancet and the editor called statements in the paper “utterly false.” Several large studies around the world have refuted Wakefield’s claimed findings, and Wakefield was ultimately struck from the British medical register.

Nonetheless, concerns about vaccine-induced autism have persisted for decades, churning on social media and by word of mouth, and accelerated in the COVID era by the backlash against coronavirus vaccine mandates. Scott Jensen, the recently unsuccessful Republican candidate for governor in Minnesota, headlined an anti-vaccine-mandate rally in that state’s capitol building despite his state seeing a troubling 22 reported measles cases between June and November last year.

“When I was a child measles was a [rite] of passage, or childhood illness, as was chicken pox,” Scott Shoemaker, president of the anti-vaccine-mandate group Health Freedom Ohio, told HuffPost in an email, adding: “When the vaccine was released, it became a ‘deadly disease.’”

That’s false: Thousands of Civil War soldiers perished of measles, and in the first decade of nationwide tracking, in the early 20th century, there were 6,000 measles-related deaths per year on average, according to a CDC history. According to the same history, in the decade before the vaccine was introduced, an estimated 400 to 500 people died annually of the virus, on top of 1,000 estimated encephalitis cases and 48,000 hospitalizations.

Measles, mumps and rubella vaccination rates have fallen across the country during the COVID-19 pandemic.

Eric Risberg/Associated Press

‘He Just Made Up A Story’

In Minnesota, anti-vaccine groups, “skeptics” and others opposed to vaccine mandates for school children ― including Wakefield ― have made their presence known at community events for years. They played in particular to anxieties in the Somali community about autism. One University of Minnesota study found that 1 in 32 Somali children in Minneapolis had autism spectrum disorder ― comparable to the rate among white children, for whom the prevalence was 1 in 36, but more than Black and Hispanic children. (The study was small and had major limitations, its lead researcher said.)

“They are everywhere. Like, every event, every forum,” Fatuma Ishtar, a community outreach worker, told Stat News of anti-vaccine activists in 2017, as a measles outbreak swept through the community. “They continue to push the community. I feel offended by this group.”

That same year, as the outbreak was ongoing in Minnesota, Columbus public health officials held forums to answer questions about vaccines from Somali Ohioans. They discussed the University of Minnesota study and emphasized the lack of any evidence of a link between autism and vaccination.

Attendees’ concerns nonetheless echoed those of millions of Americans worried about their kids’ development: “A lot of people believe the vaccination ― the MMR ― is causing autism, because when we were back home, we never had autism. So why do we have now more than zero back home?” one man asked at a forum. At another event, an attendee noted that he was concerned for his young children: “Autism is a lifetime disease.”

The health officials were clear about the existing uncertainty surrounding autism spectrum disorder. But they also stressed the lack of any evidence tying it to vaccines.

“Let me clarify about the British doctor who started it all: He lied. He just made up a story, and so we cannot trust whatever he said, because it was proven, he lied,” Tatyana Karakay, a pediatrician at Nationwide Children’s Hospital, told community members at one forum. Studies of thousands of children, she said, had failed to find a connection between the vaccine and autism. “We don’t know what causes it, and it makes all of us worried, but we know what does not.”

“When autism was first discovered, the first theory was it was bad mothers who caused it,” Karakay added. “I’m sure all of you will agree that’s not true. So we know a lot of things that don’t cause it. MMR is one of them.”

The current Ohio outbreak is not contained to one particular community, both Jones and Roberts told HuffPost ― it’s a diverse group of patients united, primarily, by being unvaccinated. And on that front, there’s some good news: Vaccination sites run by both the city of Columbus and Franklin County saw noticeable increases in MMR vaccination visits last year.

But the troubling trends in the state and nationwide have health officials worried that parents are delaying vaccines. Given that signs of autism spectrum disorder may begin to appear in early childhood, some parents wait to have their kids take the MMR shots. Rather than following the advised schedule ― one shot each at 12-15 months and 4-6 years ― some parents wait for their kids’ first shot until it’s required for school.

That leaves infants and immunocompromised children vulnerable. And even if most kids can survive a case of measles with moderate symptoms, there’s no way to know who could have more severe consequences, including encephalitis or other severe effects.

“We don’t know who is going to get really, really sick,” Jones said. “I don’t want any parent to take that chance.”

fbq('init', '1621685564716533'); fbq('track', "PageView");

var _fbPartnerID = null; if (_fbPartnerID !== null) { fbq('init', _fbPartnerID + ''); fbq('track', "PageView"); }

(function () { 'use strict'; document.addEventListener('DOMContentLoaded', function () { document.body.addEventListener('click', function(event) { fbq('track', "Click"); }); }); })();

Read original article here

Nurses go on strike at 2 big New York City hospitals

NEW YORK (AP) — Thousands of nurses went on strike Monday at two of New York City’s major hospitals after contract negotiations stalled over staffing and salaries nearly three years into the coronavirus pandemic.

The privately owned, nonprofit hospitals were postponing nonemergency surgeries, diverting ambulances to other medical centers, pulling in temporary staffers, and assigning administrators with nursing backgrounds to work in wards in order to cope with the walkout.

As many as 3,500 nurses at Montefiore Medical Center in the Bronx and about 3,600 at Mount Sinai Hospital in Manhattan were off the job. Talks were resuming Monday afternoon at Montefiore, but there was no immediate word on when bargaining might resume at Mount Sinai.

Hundreds of nurses picketed, some singing the chorus from Twisted Sister’s 1984 hit “We’re Not Gonna Take It,” outside Mount Sinai. It was one of many New York hospitals deluged with COVID-19 patients as the virus made the city an epicenter of deaths in spring 2020.

“We were heroes only two years ago,” said Warren Urquhart, a nurse in transplant and oncology units. “We was on the front lines of the city when everything came to a stop. And now we need to come to a stop so they can understand how much we mean to this hospital and to the patients.”

The nurses union, the New York State Nurses Association, said members had to strike because chronic understaffing leaves them caring for too many patients.

Jed Basubas said he generally attends to eight to 10 patients at a time, twice the ideal number in the units where he works. Nurse practitioner Juliet Escalon said she sometimes skips bathroom breaks to attend to patients. So does Ashleigh Woodside, who said her 12-hour operating-room shifts often stretch to 14 hours because short staffing forces her and others to work overtime.

“We love our job. We want to take care of our patients. But we just want to do it safely and in a humane way, where we feel appreciated,” Woodside said.

The hospitals said they had offered the same raises — totaling 19% over three years — that the union had accepted at several other facilities where contract talks reached tentative agreements in recent days.

Montefiore said it had agreed to add 170 more nurses. Mount Sinai’s administration said the union’s focus on nurse-to-patient ratios “ignores the progress we have made to attract and hire more new nurses, despite a global shortage of healthcare workers that is impacting hospitals across the country.”

The hospitals said Monday that they had prepared for the strike and were working to minimize the disruption. Mount Sinai called the union’s behavior “reckless,” while Montefiore said the strike was sparking “fear and uncertainty across our community.”

“In my opinion, this action was totally unnecessary,” Montefiore President Dr. Philip Ozuah told staffers in a memo Monday afternoon. Ozuah maintained that the two sides had been close to agreement on “a very generous offer.”

Some patients, meanwhile, were left in limbo.

Darcy Gervasio took medical leave from her job at a suburban college library, made child care and transportation arrangements, got tests and otherwise prepared for a gastrointestinal surgery that was scheduled Monday but now is postponed indefinitely, she said. While the procedure is considered elective, Gervasio said it’s essential to controlling her Crohn’s disease.

“As a patient, of course, I am annoyed and inconvenienced,” she wrote in an email. But Gervasio, a union member herself, said she blames the hospital management, not the nurses.

“I am very disappointed in the administration for letting the nursing staffing crisis get out of hand in the first place — especially in the wake of the tremendous strain on nurses during the COVID pandemic,” Gervasio wrote. She questioned why Mount Sinai couldn’t strike a deal with the union when several other local hospitals did in the last two weeks.

Gov. Kathy Hochul urged the union and the hospitals late Sunday to take their dispute to binding arbitration. Montefiore’s administration had said it was willing to let an arbitrator settle the contract; the union did not immediately accept the proposal. In a statement, it said Hochul, a Democrat, “should listen to the frontline COVID nurse heroes and respect our federally-protected labor and collective bargaining rights.”

A lineup of other city and state Democratic politicians, including Attorney General Letitia James, joined a midday union rally Monday.

Both hospitals had prepared for the walkout by transferring patients, including intensive-care newborns at Mount Sinai. State Health Department representatives were at the two medical centers Monday to monitor staffing levels, the agency said.

Montefiore and Mount Sinai are the last of a group of hospitals with nursing contracts that expired simultaneously. The union initially warned that it would strike at all of them at the same time, but the other hospitals reached agreements as the deadline approached. All include raises of 7%, 6%, and 5% over the next three years.

___

Associated Press writer Karen Matthews contributed to this report.

Read original article here

COVID-19 vaccines: From nasal drops to a redesign, what 2023 could have in store

Several vaccine companies say they are expecting breakthroughs as early as this year as they pursue new ways to protect people against SARS-CoV-2, the virus that causes COVID-19.

The Food and Drug Administration is set to convene a panel of its outside vaccine advisers later this month to weigh key issues over the future of COVID-19 vaccines, including when and how to greenlight new boosters and changes to which strain the vaccines target.

Here’s a peek at some of what’s expected this year for the next generation of COVID-19 vaccines.

New vaccines by nose or mouth

Several companies have been pursuing approaches that could offer better protection against infections themselves, instead of merely blunting the severity of the disease. 

Potential vaccines to build this kind of “mucosal immunity” aim to bring antibodies to fend off the virus at the sites where it first enters the body, through vaccines that could be taken through drops, sprays or pills.

A few of these vaccines have been licensed in other countries, but none in the U.S. — and the data behind them isn’t robust, said Dr. John Beigel, associate director for clinical research at the National Institute of Allergy and Infectious Diseases.

Even if Congress had granted the Biden administration’s request to pour resources into developing potential next-generation mucosal vaccines to broad clinical trials, Beigel said it would be challenging to “pick the winners” for government backing. 

Scientists have ways of measuring the immune responses after mucosal vaccines, like they do with the current shots. But they don’t necessarily know how those numbers will actually translate into real-world protection against the disease.

Different companies have researched mucosal vaccines for COVID, but the data is small and fragmented, Beigel said, using different methods and benchmarks. This makes it difficult for scientists to compare early results from labs that have tried out new vaccines in animals.

“I think what needs to happen is a much more organized platform where we start evaluating some of the most promising and figure out how to measure, how to ascertain, which of these are the most likely to be successful,” said Beigel.

One of the few mucosal vaccines to reach the final stage of clinical trials so far is an intranasal option produced by the company Codagenix. A large study backed by the World Health Organization of the vaccine, which is administered through drops in the nose, is expected to announce results by the end of the first quarter. A trial of the vaccine as a booster was also launched last year in the United Kingdom.

The company’s CEO J. Robert Coleman was optimistic about the vaccine’s chances of entering the U.S. market, and said what sets their vaccine apart from the rest of the field is the prospect of data showing its direct efficacy. 

Another possible mucosal vaccine could soon head into so-called “challenge trials” taken as a pill, says Vaxart CEO Sean Tucker. 

His company inked a deal with British firm hVIVO in June to develop the “world’s first human Omicron challenge model,” which will deliberately infect vaccinated volunteers with the virus in hopes of accelerating their findings. hVIVO is currently working on validating the results from their approach, Tucker said.

“They have not announced their timing about when they are going to complete that but, assuming everything goes nicely, it happens this year, and potentially we could evaluate our vaccine either this year or next year,” said Tucker.

Regulators in China approved CanSino Biologics repackaging their earlier vaccine into a nasal spray. India has also greenlighted an option produced by Bharat Biotech. Ocugen, that vaccine’s American sponsor, hopes to launch trials that could pave the way for a rollout in the U.S. market.

“We would like to make Ocugen’s mucosal vaccine available as soon as possible and are pursuing opportunities for government funding to support the development of OCU500,” Tiffany Hamilton, a spokesperson for Ocugen, said in an email.

However, scientists and U.S. officials voiced skepticism over these already-licensed options, given an attempt by AstraZeneca and the University of Oxford yielded disappointing results last year. 

“It is also not at all clear from well-controlled clinical trials that administering existing vaccines by the intranasal route (as some countries have already even approved) will provide truly meaningful benefit over the existing generation,” wrote the authors of a viewpoint co-authored last month by Dr. Peter Marks, the FDA’s top vaccines official. 

Changes to existing vaccines

Novavax and Moderna, as well as Pfizer and BioNTech, say they are pursuing clinical trials of versions of their COVID-19 vaccines blended with components designed to trigger immunity against influenza or RSV in a single shot.

The current batch of updated “bivalent” COVID boosters are already a combination vaccine of sorts, blending together an antigen aimed at the original strain of the virus with another designed for the BA.4 and BA.5 variants.

“A combination influenza and COVID vaccine — that still looks very optimistic that that might be available for next season, and I think it might do something good to combat the vaccine fatigue that’s out there at the moment,” says Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center.

Some traditional vaccine manufacturers have also announced plans for revisions they hope can improve the length or breadth of immunity offered by current shots. Pfizer and BioNTech launched a study in November targeting “non-spike proteins” commonly seen across variants.

“I’d like to think that we are not going to keep chasing variants. I’d like to think that we’re not going to be recommending a yearly vaccine, which I think also doesn’t make sense. The flu model does not make sense for coronavirus,” said Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia. He was one of two votes against updating the vaccines for BA.4 and BA.5 in June.

These days, a growing share of infections are being driven by a “recombinant” descendant of BA.2 strains known as XBB.1.5. The updated boosters are expected to offer “some” improved protection against it, the FDA says.

“I don’t think the goal is to try and protect against mild disease,” added Offit, who said he was skeptical that immunity from either infections or vaccinations would ever be able to block the onslaught of immune-evasive strains.

The regulator is expected to grapple with the immediate question of what strains should be targeted by vaccines as a large swath of the country’s current “monovalent” supply is due to expire. 

“If we vaccinate only against the viruses that are circulating now, will they be more liable to get infected with ones that were present early in the pandemic, and no longer are present?” said Dr. Stanley Perlman of the University of Iowa. 

Perlman, who is also a member of the FDA vaccines panel, said he was on the fence on whether components targeting the original strain are still needed.

“I know that I was more of a fan of a bivalent vaccine that was decided in June,” said Perlman. “But now I don’t know. I think we just have to see how the virus plays out.”



Read original article here

Travelers rush to take advantage of China reopening

BEIJING (AP) — After two years of separation from his wife in mainland China, Hong Kong resident Cheung Seng-bun made sure to be among the first in line following the reopening of border crossing points Sunday.

The ability of residents of the semi-autonomous southern Chinese city to cross over is one of the most visible signs of China’s easing of border restrictions, with travelers arriving from abroad also no longer required to undergo quarantine.

“I’m hurrying to get back to her,” Cheung, lugging a heavy suitcase, told The Associated Press as he prepared to cross at Lok Ma Chau station.

Travelers crossing between Hong Kong and mainland China, however, are still required to show a negative COVID-19 test taken within the last 48 hours — a measure China has protested when imposed by other countries.

Hong Kong has been hard-hit by the virus, and its land and sea border checkpoints with the mainland have been largely closed for almost three years. Despite the risk of new infections, the reopening that will allow tens of thousands of people who have made prior online bookings to cross each day is expected to provide a much-needed boost to Hong Kong’s tourism and retail sectors.

On a visit to the station Sunday morning, Hong Kong’s Chief Executive John Lee said the sides would continue to expand the number of crossing points from the current seven to the full 14.

“The goal is to get back as quickly as possible to the pre-epidemic normal life,” Lee told reporters. “We want to get cooperation between the two sides back on track.”

Communist Party newspaper Global Times quoted Tan Luming, a port official in Shenzhen on the border with Hong Kong, saying about 200 passengers were expected to take the ferry to Hong Kong, while another 700 were due to travel in the other direction, on the first day of reopening. Tan said a steady increase in passenger numbers is expected over coming days.

“I stayed up all night and got up at 4:00 a.m. as I’m so excited to return to the mainland to see my 80-year-old mother,” a Hong Kong woman identified only by her surname, Cheung, said on arrival at Shenzhen, where she was presented with “roses and health kits,” the paper said.

Hong Kong media reports said around 300,000 travel bookings from the city to mainland China have already been made.

Limited ferry service had also been restored from China’s Fujian province to the Taiwanese-controlled island of Kinmen just off the Chinese coast.

The border crossing with Russia at Suifenhe in the far northern province of Heilongjiang also resumed normal operations, just in time for the opening of the ice festival in the capital of Harbin, a major tourism draw.

China’s borders remain largely sealed, however, with only a fraction of the previous number of international flights arriving at major airports.

Beijing’s main Capital International Airport was expecting eight flights from overseas on Sunday, according to the airport. Shanghai, China’s largest city, received its first international flight under the new policy at 6:30 a.m. with only a trickle of other international flights to follow.

That number is expected now to tick upward, with booking inquiries for overseas flights overwhelming some online travel services ahead of the Lunar New Year travel rush later this month. Capital International is preparing to reopen arrival halls that have been quiet for most of the past three years.

Shanghai, meanwhile, announced it would again start issuing regular passports to Chinese for foreign travel and family visits, as well as renewing and extending visas for foreigners. Those restrictions have had a particularly devastating effect on foreign businesspeople and students in the key Asian financial center.

China is now facing a surge in cases and hospitalizations in major cities and is bracing for a further spread into less developed areas with the start of China’s most important holiday of the year, set to get underway in coming days.

Authorities say they expect domestic rail and air journeys will double over the same period last year, bringing overall numbers close to those of the 2019 holiday period before the pandemic hit.

Meanwhile, the controversy continues over testing requirements being imposed on Chinese travelers by foreign governments — most recently Germany and Sweden. On Saturday, German Foreign Minister Annalena Baerbock urged citizens to avoid “unnecessary” travel to China, noting the rise in coronavirus cases in the country and saying that China’s Health system is “overburdened.”

The German regulation also allows for spot checks on arrival and Germany, like other European nations, will test wastewater from aircrafts for possible new virus variants. The measures come into force at midnight Monday and are due to last until April 7.

Apparently concerned about its reputation, China says the testing requirements aren’t science-based and has threatened unspecified countermeasures.

Chinese health authorities publish a daily count of new cases, severe cases and deaths, but those numbers include only officially confirmed cases and use a very narrow definition of COVID-19-related deaths.

Authorities say that since the government ended compulsory testing and permitted people with mild symptoms to test themselves and convalesce at home, it can no longer provide a full picture of the state of the latest outbreak.

Government spokespeople have said the situation is under control and reject accusations from the World Health Organization and others that it is not being transparent about the number of cases and deaths or providing other crucial information on the nature of the current outbreak that could lead to the emergence of new variants.

Despite such assertions, the Health Commission on Saturday rolled out regulations for strengthened monitoring of viral mutations, including testing of urban wastewater. The lengthy rules called for increased data gathering from hospitals and local government health departments and stepped-up checks on “pneumonia of unknown causes.”

Criticism has largely focused on heavy-handed enforcement of regulations, including open-ended travel restrictions that saw people confined to their homes for weeks, sometimes sealed inside without adequate food or medical care.

Anger was also vented over the requirement that anyone who potentially tested positive or had been in contact with such a person be confined for observation in a field hospital, where overcrowding, poor food and hygiene were commonly cited.

The social and economic costs eventually prompted rare street protests in Beijing and other cities, possibly influencing the Communist Party’s decision to swiftly ease the strictest measures and reprioritize growth.

As part of the latest changes, China will also no longer bring criminal charges against people accused of violating border quarantine regulations, according to a notice issued by five government departments on Saturday.

Individuals currently in custody will be released and seized assets returned, the notice said.

The Transportation Ministry on Friday called on travelers to reduce trips and gatherings, particularly if they involve elderly people, pregnant women, small children and those with underlying conditions.

___

Associated Press reporters Alice Fung and Karmen Li in Hong Kong and Frank Jordans in Berlin contributed to this report.

Read original article here

Most people who ended up with long COVID started with a mild case, new study shows

Sarah Wulf Hanson is the lead research scientist of Global Health Metrics at the University of Washington and Theo Vos is a professor of health metric sciences with the University of Washington.


The big idea

Even mild COVID-19 cases can have major and long-lasting effects on people’s health. That is one of the key findings from our recent multicountry study on long COVID-19 – or long COVID – recently published in the Journal of the American Medical Association.

Long COVID is defined as the continuation or development of symptoms three months after the initial infection from SARS-CoV-2, the virus that causes COVID-19. These symptoms last for at least two months after onset with no other explanation.

We found that a staggering 90% of people living with long COVID initially experienced only mild illness with COVID-19. After developing long COVID, however, the typical person experienced symptoms including fatigue, shortness of breath and cognitive problems such as brain fog – or a combination of these – that affected daily functioning. These symptoms had an impact on health as severe as the long-term effects of traumatic brain injury. Our study also found that women have twice the risk of men and four times the risk of children for developing long COVID.

We analyzed data from 54 studies reporting on over 1 million people from 22 countries who had experienced symptoms of COVID-19. We counted how many people with COVID-19 developed clusters of new long-COVID symptoms and determined how their risk of developing the disease varied based on their age, sex and whether they were hospitalized for COVID-19.

We found that patients who were hospitalized for COVID-19 had a greater risk of developing long COVID – and of having longer-lasting symptoms – compared with people who had not been hospitalized. However, because the vast majority of COVID-19 cases do not require hospitalization, many more cases of long COVID have arisen from these milder cases despite their lower risk. Among all people with long COVID, our study found that nearly one out of every seven were still experiencing these symptoms a year later, and researchers don’t yet know how many of these cases may become chronic.

Why it matters

Compared with COVID-19, relatively little is known about long COVID.

Our systematic, multicountry analysis of this condition delivered findings that illuminate the potentially steep human and economic costs of long COVID around the world. Many people who are living with the condition are working-age adults. Being unable to work for many months could cause people to lose their income, their livelihoods and their housing. For parents or caregivers living with long COVID, the condition may make them unable to care for their loved ones.

We think, based on the pervasiveness and severity of long COVID, that it is keeping people from working and therefore contributing to labor shortages. Long COVID could also be a factor in how people losing their jobs has disproportionately affected women.

We believe that finding effective and affordable treatments for people living with long COVID should be a priority for researchers and research funders. Long COVID clinics have opened to provide specialized care, but the treatments they offer are limited, inconsistent and may be costly.

What’s next

Long COVID is a complex and dynamic condition – some symptoms disappear, then return, and new symptoms appear. But researchers don’t yet know why.

While our study focused on the three most common symptoms associated with long COVID that affect daily functioning, the condition can also include symptoms like loss of smell and taste, insomnia, gastrointestinal problems and headaches, among others. But in most cases these additional symptoms occur together with the main symptoms we made estimates for.

There are many unanswered questions about what predisposes people to long COVID. For example, how do different risk factors, including smoking and high body-mass index, influence people’s likelihood of developing the condition? Does getting reinfected with SARS-CoV-2 change the risk for long COVID? Also, it is unclear how protection against long COVID changes over time after a person has been vaccinated or boosted against COVID-19.

COVID-19 variants also present new puzzles. Researchers know that the Omicron variant is less deadly than previous strains. Initial evidence shows lower risk of long COVID from Omicron compared with earlier strains, but far more data is needed.

Most of the people we studied were infected with the deadlier variants that were circulating before omicron became dominant. We will continue to build on our research on long COVID as part of the Global Burden of Disease study – which makes estimates of deaths and disability due to all diseases and injuries in every country in the world – in order to to get a clearer picture of how COVID-19’s long-term toll shifted once omicron arrived.

This article is republished from The Conversation under a Creative Commons license.

Read original article here

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

Following the large-scale rollout of the messenger ribonucleic acid (mRNA) vaccines developed to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and symptomatic coronavirus disease 2019 (COVID-19), several cases of myocarditis were reported, mostly among healthy young people.

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

Study: Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis. Image Credit: Design_Cells / Shutterstock

Introduction

The development of myocarditis following mRNA vaccination is rare, occurring in <2 per 100,000 individuals. It remains an unpredictable mysterious occurrence. Some have suggested that it is linked to the overproduction of antibodies or abnormal immune responses.

Autoantibody production due to polyclonal B cell activation and proliferation has also been suggested, as has immune complex formation and inflammation. Finally, some think that cardiac antigens closely resembling the spike protein are targeted by autoantibodies formed as a result of molecular mimicry.

The immune response to these vaccines in these patients needs to be better understood in order to determine why and how it happens. It is imperative to study the role of male hormones since young male patients are most often affected.

The researchers in this study looked at blood samples from 16 myocarditis patients, confirmed to have high levels of serum cardiac troponin T. All developed myocarditis after receiving the COVID-19 vaccine, typically within a week of the second dose. However, a few became sick after the first dose or booster dose. Over 80% were male.

They were studied by antibody profiling, including antibodies to the virus, autoantibodies or antibodies to the virome, and the analysis of T cells specifically directed against the virus. In addition, cytokine and antigen profiles were determined. These measurements were compared with those of 45 vaccinated controls, who were of similar age and health.

What did the study show?

All subjects and controls showed a rise in anti-spike antibodies and antibodies to the receptor binding domain (RBD), of all immunoglobulin (Ig) subclasses, IgA, IgM, and IgG. Functional differences were not perceived either, with Fc effector functions being similar in both categories. In short, all vaccinated individuals showed evidence of a protective immune response against the virus.

We found no indication that a specific antibody response is associated with myocarditis.”

Additionally, these patients did not show evidence of increased autoantibody production or antibody production against other respiratory pathogens that differed in magnitude or range from the controls.

T cells of all relevant subtypes, including naïve, memory, and effector memory T cells, showed similar distributions in both groups. T cells also showed similar proportions of spike-specific memory CD4 T cells and activated CD4 and CD8 T cells. The only exceptions were the observation of small elevations in effector memory cells and PD-1-expressing bulk CD4 T cells in the myocarditis group.

The findings indicated that antibody and T-cell responses could not distinguish between post-vaccine myocarditis subjects and vaccinated controls. The only significant difference was a slight elevation in cytokine production in the former.

The exciting difference was the high level of circulating full-length spike protein in the plasma of myocarditis patients, at a mean of ~34 pg/mL. Furthermore, the protein was not bound to antibodies and remained detectable for up to three weeks from the vaccination date. In contrast, controls did not have free spike protein in their blood.

This difference could not be attributed to poor neutralizing capacity in the myocarditis group, which showed comparable neutralization relative to the control group.

Concordantly, myocarditis patients had cytokine release patterns resembling those found in multisystem inflammatory syndrome in children (MIS-C). This might indicate that the innate immune response was overactive, leading to elevations in interleukin (IL)-8, IL-10, IL-4, IL-6, tumor necrosis factor (TNF)-α, and interferon (INF)-γ relative to healthy controls. IL-8 was most closely associated with raised cardiac troponin T and antigen levels.

Alongside, leukocytes, especially neutrophils, were at higher mean levels in this group than controls, though still within normal range.

What are the implications?

The study shows that the immunological response elicited by the mRNA vaccine was very similar in those who developed post-vaccination myocarditis and others. In other words, myocarditis could not be associated with abnormal autoantibodies, viral infections other than SARS-CoV-2, or excessive production of antibodies elicited by the mRNA vaccine.

In vaccinated patients, infection with the virus was not likely to be a cause or contributing factor for myocarditis since anti-Nucleoprotein IgG was not found in these patients.

In contrast to controls, the finding of high levels of unbound full-length spike protein in myocarditis patients may point to the mechanism by which this condition arises. Similarly, MIS-C patients had circulating SARS-CoV-2 antigens.

The spike protein appears to evade immune antibodies found at normal levels in these patients, with adequate functional and neutralization capacity. The spike may damage the cardiac pericytes or endothelium, perhaps by reducing the expression of the angiotensin-converting enzyme 2 (ACE2), reducing nitric oxide production in the endothelium, or activating inflammation via integrins, causing the endothelium to become abnormally permeable.

Thus, the spike antigen itself, which evades antibody recognition rather than invoking immune hyperactivation, may contribute to myocarditis in these individuals.”

This finding does not amount to evidence against the benefit of vaccination with these vaccines, which effectively protect against severe COVID-19 outcomes. Therefore, current vaccine recommendations are unlikely to be altered due to these results.

Understanding the immunopathological mechanisms associated with postvaccine myocarditis will help improve safety and guide the development of future coronavirus disease 2019 (COVID-19) vaccines. These findings also suggest that administration of anti-spike antibodies, if spike antigenemia is detected, could potentially prevent or reverse postvaccine myocarditis.”

Read original article here

Free spike proteins in the blood appear to play a role in myocarditis post-COVID mRNA vaccine

Following the large-scale rollout of the messenger ribonucleic acid (mRNA) vaccines developed to prevent infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and symptomatic coronavirus disease 2019 (COVID-19), several cases of myocarditis were reported, mostly among healthy young people.

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

Study: Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis. Image Credit: Design_Cells / Shutterstock

Introduction

The development of myocarditis following mRNA vaccination is rare, occurring in <2 per 100,000 individuals. It remains an unpredictable mysterious occurrence. Some have suggested that it is linked to the overproduction of antibodies or abnormal immune responses.

Autoantibody production due to polyclonal B cell activation and proliferation has also been suggested, as has immune complex formation and inflammation. Finally, some think that cardiac antigens closely resembling the spike protein are targeted by autoantibodies formed as a result of molecular mimicry.

The immune response to these vaccines in these patients needs to be better understood in order to determine why and how it happens. It is imperative to study the role of male hormones since young male patients are most often affected.

The researchers in this study looked at blood samples from 16 myocarditis patients, confirmed to have high levels of serum cardiac troponin T. All developed myocarditis after receiving the COVID-19 vaccine, typically within a week of the second dose. However, a few became sick after the first dose or booster dose. Over 80% were male.

They were studied by antibody profiling, including antibodies to the virus, autoantibodies or antibodies to the virome, and the analysis of T cells specifically directed against the virus. In addition, cytokine and antigen profiles were determined. These measurements were compared with those of 45 vaccinated controls, who were of similar age and health.

What did the study show?

All subjects and controls showed a rise in anti-spike antibodies and antibodies to the receptor binding domain (RBD), of all immunoglobulin (Ig) subclasses, IgA, IgM, and IgG. Functional differences were not perceived either, with Fc effector functions being similar in both categories. In short, all vaccinated individuals showed evidence of a protective immune response against the virus.

We found no indication that a specific antibody response is associated with myocarditis.”

Additionally, these patients did not show evidence of increased autoantibody production or antibody production against other respiratory pathogens that differed in magnitude or range from the controls.

T cells of all relevant subtypes, including naïve, memory, and effector memory T cells, showed similar distributions in both groups. T cells also showed similar proportions of spike-specific memory CD4 T cells and activated CD4 and CD8 T cells. The only exceptions were the observation of small elevations in effector memory cells and PD-1-expressing bulk CD4 T cells in the myocarditis group.

The findings indicated that antibody and T-cell responses could not distinguish between post-vaccine myocarditis subjects and vaccinated controls. The only significant difference was a slight elevation in cytokine production in the former.

The exciting difference was the high level of circulating full-length spike protein in the plasma of myocarditis patients, at a mean of ~34 pg/mL. Furthermore, the protein was not bound to antibodies and remained detectable for up to three weeks from the vaccination date. In contrast, controls did not have free spike protein in their blood.

This difference could not be attributed to poor neutralizing capacity in the myocarditis group, which showed comparable neutralization relative to the control group.

Concordantly, myocarditis patients had cytokine release patterns resembling those found in multisystem inflammatory syndrome in children (MIS-C). This might indicate that the innate immune response was overactive, leading to elevations in interleukin (IL)-8, IL-10, IL-4, IL-6, tumor necrosis factor (TNF)-α, and interferon (INF)-γ relative to healthy controls. IL-8 was most closely associated with raised cardiac troponin T and antigen levels.

Alongside, leukocytes, especially neutrophils, were at higher mean levels in this group than controls, though still within normal range.

What are the implications?

The study shows that the immunological response elicited by the mRNA vaccine was very similar in those who developed post-vaccination myocarditis and others. In other words, myocarditis could not be associated with abnormal autoantibodies, viral infections other than SARS-CoV-2, or excessive production of antibodies elicited by the mRNA vaccine.

In vaccinated patients, infection with the virus was not likely to be a cause or contributing factor for myocarditis since anti-Nucleoprotein IgG was not found in these patients.

In contrast to controls, the finding of high levels of unbound full-length spike protein in myocarditis patients may point to the mechanism by which this condition arises. Similarly, MIS-C patients had circulating SARS-CoV-2 antigens.

The spike protein appears to evade immune antibodies found at normal levels in these patients, with adequate functional and neutralization capacity. The spike may damage the cardiac pericytes or endothelium, perhaps by reducing the expression of the angiotensin-converting enzyme 2 (ACE2), reducing nitric oxide production in the endothelium, or activating inflammation via integrins, causing the endothelium to become abnormally permeable.

Thus, the spike antigen itself, which evades antibody recognition rather than invoking immune hyperactivation, may contribute to myocarditis in these individuals.”

This finding does not amount to evidence against the benefit of vaccination with these vaccines, which effectively protect against severe COVID-19 outcomes. Therefore, current vaccine recommendations are unlikely to be altered due to these results.

Understanding the immunopathological mechanisms associated with postvaccine myocarditis will help improve safety and guide the development of future coronavirus disease 2019 (COVID-19) vaccines. These findings also suggest that administration of anti-spike antibodies, if spike antigenemia is detected, could potentially prevent or reverse postvaccine myocarditis.”

Read original article here

Ways to Regain Sense of Smell After COVID

Among the many aftereffects of COVID-19 infection, one that has garnered much attention is the loss of smell or taste. For many people, the condition is long-term and treatment remains elusive.

Why does this happen to some people and are there effective treatments available to restore our sense of smell after COVID?

Loss of Smell Is Common With Many Viral Infections

Our sense of taste and smell work together to help us enjoy food and drink. The loss of these senses can make meals seem tasteless or bland. More importantly, we may not recognize potentially dangerous situations like a gas leak or spoiled food.

Losing taste (ageusia) and smell (anosmia) is not only an early symptom of COVID-19 infection—it’s also a well-known symptom of long COVID.

However, the condition isn’t unique to COVID.

“Loss of smell is common with numerous viral infections, and especially so in COVID. In about 95 percent, smell has returned by 6 months,” Jacob Teitelbaum, M.D., a board-certified internist and nationally known expert in the fields of chronic fatigue syndrome, fibromyalgia, sleep, and pain, told The Epoch Times.

In a study from New York University, researchers found that the presence of COVID virus near nerve cells in olfactory tissue stimulated an inrush of immune cells, like microglia and T cells to counter the infection. 

These cells release proteins called cytokines that change genetic activity in olfactory cells, even though the virus couldn’t infect them. In other scenarios, immune cell activity dissipates quickly; but researchers theorize that COVID-related immune signaling persists in a way that impairs the activity of genes needed to build smell receptors.

Other research found why, for some people, the loss is potentially permanent.

Scientists at Duke University, with experts from Harvard University and the University of California San Diego, used a tissue biopsy (extracted sample) to analyze olfactory epithelial cells, particularly those from COVID patients with long-term anosmia.

The findings indicate our immune cells may continue reacting, even when the threat is gone. 

Analyses revealed widespread infiltration by T-cells (immune cells) that caused an inflammatory response in the nose where the nerve cells for smell are located. 

“The findings are striking,” senior author Bradley Goldstein, M.D., associate professor in Duke’s Department of Neurobiology, said in a statement.

“It’s almost resembling a sort of autoimmune-like process in the nose,” he noted.

Regaining Our Sense of Smell, Steroid Nasal Spray Shows Promise

A study published in the American Journal of Otolaryngology found fluticasone (Flonase) nasal spray helped participants regain their sense of smell.

Researchers looked at 120 people experiencing anosmia due to COVID-19 and split them into two groups—one that received treatment and one that did not.

They found that smell and taste function significantly improved within one week in all patients with COVID-19 who received fluticasone nasal spray.

Teitelbaum said the nasal spray may work because viral infections can cause inflammation and swelling around the olfactory nerves. Fluticasone is an over-the-counter steroid nasal spray that reduces inflammation.

“Once the infection has been gone for a month,” advised Teitelbaum. “The OTC steroid nasal spray Flonase [used] for 6 to 8 weeks may decrease the nasal and nerve swelling.”

But he cautioned that this nasal spray shouldn’t be used while symptoms of active infection, like a runny nose, are present.

Olfactory Retraining

Anosmia has been studied long before the current pandemic. A 2009 study discovered that the sense of smell could be re-sensitized in people who lost the ability to detect odors.

Researchers exposed participants to one of four odors: cloves, lemon, eucalyptus, and rose.

Patients sniffed the four intense odors twice a day for 12 weeks. They were tested for sensitivity before and after training using “Sniffin’ Sticks” of various smell intensities.   

Compared to the baseline, patients who trained their olfactories experienced an increase in their sensitivity to smells, according to their Sniffin’ Sticks test score. Smell sensitivity was unchanged in patients who didn’t receive the sense training.

Research specifically looking at people with COVID-related loss of smell found that smell training effectively improved their ability to detect odors.

“When begun early and with good compliance, olfactory training was reported to be most beneficial in enhancing olfactory function,” said Teitelbaum.

Vitamins That May Help

There are many theories about what causes loss of smell in COVID, but we still don’t know exactly why. 

Teitelbaum believes it’s likely a mix of several causes, including low levels of certain nutrients, such as zinc.

“I give 25 to 50 mg [of zinc] a day for 6 months [to patients],” he said.

Zinc is critical for immune function, with the key immune regulating hormone called thymulin being zinc-dependent. Many infections, including AIDS, deplete zinc to worsen immunity. Smell is also zinc-dependent.

Another key nutrient for smell is vitamin A. 

“The retinol form of vitamin A at doses of 2500 to 5000 units a day may, along with zinc [at] 25 to 50 mg a day, help smell over time,” Teitelbaum recommended. 

However, pregnant women need to be careful when taking this vitamin. “Vitamin A will cause birth defects in pregnant women at doses over 8000 units,” Teitelbaum warned. 

A case study from 2021 describes how a COVID-19 patient’s ability to smell was restored by olfactory training combined with daily doses of these B-complex vitamins:

  • 5000 IU of vitamin B1  
  • 100 mg of vitamin B6  
  • 5000 mg of vitamin B12 

The patient’s anosmia was significantly improved at 12 days and his sense of smell was recovered by day 40.  

George Citroner is a health reporter for The Epoch Times.

Read original article here